wheezo® includes a digital wheeze monitor and eHealth app that records and analyses breath sounds for the presence of wheeze, the sound your doctor listens for with a stethoscope.

Over time, wheezo® builds a clearer picture of your asthma by collating data^ that can be shared with health professionals. This information is instantly accessible and shareable via the app.

^Asthma data refers to self-reported symptoms, triggers, peak flow measurements and medication use.

A Special Offer for Australian Patients Association Members
$30.00 off + Free Shipping

When you purchase a wheezo® digital wheeze monitor with a 12-month annual subscription (billed annually). Terms and Conditions apply.

By purchasing wheezo® with a 12-month annual subscription (once-off payment), you will also receive a month of free subscription to the wheezo® premium eHealth app that stores an Asthma Action Plan and other self-reported triggers, medication use and peak flow measurements.

To learn more and redeem the offer click below.

Redeem Now

Learn about your asthma and work with your healthcare professional to assist with asthma management.

With wheezo® you can:

  • Record wheeze and log your symptoms* and triggers*
  • Monitor air quality pollen counts down to your postcode in real time
  • Digitise your Asthma Action Plan
  • Document your medication and set reminders
  • Review your history and share it with your Healthcare Providers
  • Access the online portal to view your data & trends over time

*self-reported

Offer Terms and Conditions
$30.00 off + Free Shipping

† Only valid when a wheezo® digital wheeze monitor and a 12-month annual wheezo® premium app subscription (billed annually) are purchased together in one transaction. To receive the APA discount via email, click on to the link above and you will be redirected to a website where you can enter your email address. You will be sent an email with a link to purchase. Offer can only be redeemed via the link. Offer is not valid on subscriptions which are billed monthly.

Financial Disclosure: The Australian Patients Association (APA) receives funding from Respiri Limited for promoting its offering. The receipt and use of these funds does not in any way affect the integrity of the APA’s service to patients or commitment to empower patients with the information they need.

Always read the instructions for use. People with asthma should consult their healthcare professional about their medical condition, their medications and the information collected within the wheezo as a part of their overall asthma management. Regardless of the wheeze rate, if the user has signs and symptoms such as chest tightness, shortness of breath, coughing or wheezing, they should always follow their healthcare professional’s advice and their asthma action plan.

wheezo is a home monitoring device and is not intended for diagnostic use. When wheezo is used to monitor wheezing in lung conditions such as asthma, the user should be under the care of a licensed healthcare professional.

wheezo is entered in the ARTG, 327306, with CE mark. wheezo® is a registered trademark of Respiri Limited. Respiri Limited, ACN – 009 234 173, Level 9, 432 St Kilda Road, Melbourne, VIC 3004. Ph 1300 11 RESP (1300 11 7377). Date of preparation: Aug 2021. RESP281.